Saturday 17 October 2026
Export IRWD’s income statement to Excel — free account
Ironwood Pharmaceuticals, Inc.
IRWD Healthcare Drug Manufacturers Specialty & Generic
Ironwood Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $296.2 million, down 15.7% from fiscal 2024. In the quarter to June 2026, revenue grew 32.6%, EPS grew 106.7%, free cash flow grew 486.7% and total debt was flat, each against the same quarter a year earlier.
3.50
0.27
−7.16%
Follow IRWD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
7.10 | 21.38 | 5.51 | 5.28 |
P/S ratio |
0.63 | 1.84 | 1.59 | 1.78 | |
P/FCF ratio |
3.14 | 4.29 | 5.11 | 3.73 | |
P/Operating CF |
4.47 | 7.31 | 112.03 | 11.88 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.94 | 3.09 | 2.59 | 3.08 | |
EV/EBITDA |
5.25 | 9.11 | 4.64 | 5.08 | |
EV/Operating CF |
9.70 | 7.20 | 8.36 | 6.46 | |
EV/FCF |
9.71 | 7.20 | 8.36 | 6.46 | |
Quick Ratio |
1.08 | 1.08 | 1.38 | 5.84 | |
Current Ratio |
1.13 | 1.13 | 1.41 | 6.06 | |
Net Debt/EBITDA |
5.85 | 50.82 | 4.99 | 3.83 | |
Debt/Assets |
147.58% | 147.31% | 134.58% | 135.03% | |
Debt/Equity |
(2.21) | (2.23) | (2.69) | (2.38) | |
Asset Turnover |
0.86 | 0.79 | 0.95 | 1.24 | |
Operating CF/Net income |
1.19 | (32.77) | 0.13 | 1.14 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
8.95 | 0.86 | 7.94 | 11.01 | |
Research and Development Expense of Revenue |
18.41% | 45.83% | 20.60% | 19.83% | |
Selling, General and Administrative Expense of Revenue |
17.95% | 40.44% | 11.30% | 10.01% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.00 | 0.01 | |
Share Based Compensation of Revenue |
2.96% | 8.01% | 3.43% | 2.86% | |
Graham Net Nets |
(1.82) | (0.71) | (0.56) | (0.36) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
14.08% | 4.68% | 18.17% | 18.95% | |
Free Cash Flow Yield |
31.83% | 23.29% | 19.55% | 26.80% | |
Revenue per Share |
0.75 | 0.29 | 0.65 | 0.69 | |
Operating CF per Share |
0.29 | 0.46 | 0.03 | 0.35 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.29 | 0.46 | 0.03 | 0.35 | |
Cash per Share |
0.87 | 1.33 | 1.35 | 0.48 | |
Shareholders Equity per Share |
(1.63) | (1.62) | (1.33) | (0.98) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(1.63) | (1.62) | (1.33) | (0.98) | |
Free Cash Flow |
47.58 | 74.58 | 5.12 | 58.28 | |
Working Capital |
31.34 | 31.96 | 95.99 | 166.35 | |
Capital Expenditures |
0.00 | 0.00 | — | — | |
Net Current Asset Value |
(386.38) | (384.56) | (319.42) | (247.77) | |
EV/EBIT |
5.33 | 9.29 | 4.69 | 5.12 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
1.73 | 5.54 | 2.87 | 2.96 | |
| Other line items | |||||
Average Receivables |
98.29 | 64.32 | 72.81 | 99.45 | |
Average Payables |
2.42 | 2.51 | 4.53 | 1.15 | |
Average Assets |
392.79 | 373.90 | 380.89 | 314.04 | |
Average Common Equity |
(287.75) | (281.58) | (275.60) | (235.00) |
Columns are period end dates